274 related articles for article (PubMed ID: 18799339)
1. Bacillus Calmette-Guérin (BCG) vaccine-induced complications in children treated with highly active antiretroviral therapy.
Nuttall JJ; Davies MA; Hussey GD; Eley BS
Int J Infect Dis; 2008 Nov; 12(6):e99-105. PubMed ID: 18799339
[TBL] [Abstract][Full Text] [Related]
2. Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children.
Hesseling AC; Rabie H; Marais BJ; Manders M; Lips M; Schaaf HS; Gie RP; Cotton MF; van Helden PD; Warren RM; Beyers N
Clin Infect Dis; 2006 Feb; 42(4):548-58. PubMed ID: 16421800
[TBL] [Abstract][Full Text] [Related]
3. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children.
Hesseling AC; Marais BJ; Gie RP; Schaaf HS; Fine PE; Godfrey-Faussett P; Beyers N
Vaccine; 2007 Jan; 25(1):14-8. PubMed ID: 16959383
[TBL] [Abstract][Full Text] [Related]
4. Danish bacille Calmette-Guérin vaccine-induced disease in human immunodeficiency virus-infected children.
Hesseling AC; Schaaf HS; Hanekom WA; Beyers N; Cotton MF; Gie RP; Marais BJ; van Helden P; Warren RM
Clin Infect Dis; 2003 Nov; 37(9):1226-33. PubMed ID: 14557968
[TBL] [Abstract][Full Text] [Related]
5. Complications of bacillus Calmette-Guérin immunization in children treated with highly-active antiretroviral therapy.
Fernandes RC; Medina-Acosta E
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e361. PubMed ID: 20207181
[No Abstract] [Full Text] [Related]
6. Adverse reactions to the Bacillus Calmette-Guerin vaccine in HIV-positive infants.
Alexander A; Rode H
J Pediatr Surg; 2007 Mar; 42(3):549-52. PubMed ID: 17336197
[TBL] [Abstract][Full Text] [Related]
7. BCG-itis in two antiretroviral-treated HIV-infected infants.
de Souza Campos Fernandes RC; Medina-Acosta E
Int J STD AIDS; 2010 Sep; 21(9):662-3. PubMed ID: 21097744
[TBL] [Abstract][Full Text] [Related]
8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
9. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
Kilaru KR; Kumar A; Sippy N; Carter AO; Roach TC
HIV Med; 2006 Mar; 7(2):99-104. PubMed ID: 16420254
[TBL] [Abstract][Full Text] [Related]
10. Immune reconstitution inflammatory syndrome (IRIS) due to Bacille Calmette Guerin (BCG) in an HIV-positive child.
Kroidl A; Huck K; Weinspach S; Gudowius S; Mackenzie CR; Oette M; Häussinger D; Niehues T
Scand J Infect Dis; 2006; 38(8):716-8. PubMed ID: 16857624
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up.
Resino S; Resino R; Micheloud D; Gurbindo Gutiérrez D; Léon JA; Ramos JT; Ciria L; de José I; Mellado J; Muñoz-Fernández A;
Clin Infect Dis; 2006 Mar; 42(6):862-9. PubMed ID: 16477566
[TBL] [Abstract][Full Text] [Related]
12. Immune reconstitution inflammatory syndrome due to Mycobacterium bovis Bacillus Calmette-Guerin in infants receiving highly active antiretroviral therapy: a call for universal perinatal rapid HIV testing prior to administration of BCG immunization of neonates.
Koppel A; Leonardo-Guerrero J; Rives S; Paniagua-Torres N; Sparrow C; Beck-Sagué CM
J Trop Pediatr; 2010 Aug; 56(4):280-3. PubMed ID: 19952057
[TBL] [Abstract][Full Text] [Related]
13. CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.
McDermott AY; Terrin N; Wanke C; Skinner S; Tchetgen E; Shevitz AH
Clin Infect Dis; 2005 Dec; 41(11):1662-70. PubMed ID: 16267741
[TBL] [Abstract][Full Text] [Related]
14. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
Reddi A; Leeper SC; Grobler AC; Geddes R; France KH; Dorse GL; Vlok WJ; Mntambo M; Thomas M; Nixon K; Holst HL; Karim QA; Rollins NC; Coovadia HM; Giddy J
BMC Pediatr; 2007 Mar; 7():13. PubMed ID: 17367540
[TBL] [Abstract][Full Text] [Related]
15. Comment on Hesseling, et al. "The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children" [Vaccine 25 (2006) 14-18].
Taştan Y
Vaccine; 2007 Jun; 25(23):4513. PubMed ID: 17434241
[No Abstract] [Full Text] [Related]
16. Routine childhood bacille Calmette Guérin immunization and HIV infection.
von Reyn CF
Clin Infect Dis; 2006 Feb; 42(4):559-61. PubMed ID: 16421801
[No Abstract] [Full Text] [Related]
17. Mycobacterium bovis lymphadenitis complicating BCG immunization in an infant with symptomatic HIV-1 infection.
Marks K; Amitai Y; Engelhard D; Kori M; Maayan S
Isr J Med Sci; 1993; 29(6-7):381-2. PubMed ID: 8349456
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience of the 23-valent capsular polysaccharide pneumococcal vaccination in HIV-1-infected patients receiving highly active antiretroviral therapy: a prospective observational study.
Hung CC; Chen MY; Hsieh SM; Hsiao CF; Sheng WH; Chang SC
Vaccine; 2004 May; 22(15-16):2006-12. PubMed ID: 15121313
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
Song R; Jelagat J; Dzombo D; Mwalimu M; Mandaliya K; Shikely K; Essajee S
Pediatrics; 2007 Oct; 120(4):e856-61. PubMed ID: 17846147
[TBL] [Abstract][Full Text] [Related]
20. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up.
Phillips P; Bonner S; Gataric N; Bai T; Wilcox P; Hogg R; O'Shaughnessy M; Montaner J
Clin Infect Dis; 2005 Nov; 41(10):1483-97. PubMed ID: 16231262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
